Hi Korogi, I think the delayed approach Ehrlich has taken with regards to adding independent board members makes very good sense from a fiscal standpoint. Even if we had all the board members in place right now if I understand the NYSE and NASDAQ requirements we could not uplist at this time due to share price (and perhaps other factors), thus paying for the board members at this time is premature. That said, I also think Leo probably has already had several interviews with potential board members and it may very well be a case of as soon as we meet the other criteria we will sign the candidates and then make the application for uplisting at the same time. In this manner the costs for the board are delayed until the other criteria for uplisting are met, makes good sense to me. I also don't have any heartburn about the other issues that come to light recently like the salary increases. Lets be honest, either we trust management or we don't. Thus far I have not seen anything that raises big red flags. Ultimately Menon and Ehrlich have the most skin in the game and as of now its their locomotive and they are the conductors, we the passengers are in the caboose but more than willing at this point to have a ticket for the ride. Also uplisting will not shelter us from orchestrated short attacks, just look at NNVC, DNDN, overstock.com and others, uplisting did not shield them from manipulation. For now I am fine with where we are, which is light years ahead of where we were 15 months ago when I first purchased. Lets hope we get an updated ASCO slide this year similar to last years but this times is updated to include multiple patients with tumor reduction, still no SAE or dose limiting toxicities or confirmed p21 biomarker expression. Then its off to the races.
